Abstract
A review summarised extensive clinical, published and as yet unpublished data on the use of ambroxol in children and evaluated the results. Ambroxol was shown to be an effective secretolytic treatment in children with acute and chronic respiratory diseases. Based on the continuous monitoring of ambroxol safety over many years, the drug showed a favourable benefit-risk profile in adults and children of any age.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
